Patents by Inventor Mitesh Jivraj Borad

Mitesh Jivraj Borad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted Therapies for Cancer
    Publication number: 20180125846
    Abstract: Methods of treating, and for selecting a chemotherapy regimen for treatment of cancer in a patient (FIG. 9). For example, a patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFII and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFII is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.
    Type: Application
    Filed: August 1, 2017
    Publication date: May 10, 2018
    Applicants: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Mitesh Jivraj Borad, David Craig, John Carpten
  • Targeted therapies for cancer
    Patent number: 9750741
    Abstract: Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: September 5, 2017
    Assignees: The Translational Genomics Research Institute, MAYO Foundation for Medical Education and Research
    Inventors: Mitesh Jivraj Borad, David Craig, John Carpten
  • Targeted Therapies for Cancer
    Publication number: 20160038492
    Abstract: Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 11, 2016
    Applicants: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Mitesh Jivraj Borad, David Craig, John Carpten